Clinical Topics

Overcoming Radiation Resistant Prostate Cancer

by U.S. Medicine

April 23, 2019

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery.

The problem is that nearly 30% to 50% of patients undergoing radiotherapy develop radiation-resistant disease, according to a study in the journal Oncogene.1

A research team from the Los Angeles VAMC and Cedars-Sinai Medical Center suggested that better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome.

The researchers identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-β signaling. They found that antagonizing CD105-dependent BMP signaling with a partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with irradiation.

“In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD105/BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and PGC-1α activation,” they wrote. “Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone. However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells.”

The authors said this finding “suggested DNA damage repair was not the sole determinant of CD105 radio-resistance.”

Cancer cells undergo an energy deficit following irradiation, due to the demands of DNA and organelle repair, and the study examined SIRT1’s role on p53 and PGC-1α in terms of glycolysis and mitochondrial biogenesis, respectively. Researchers determined that blocking the CD105-SIRT1 axis depleted the ATP stores of irradiated cells and caused G2 cell cycle arrest.

Xenograft models supported these findings that combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value = 10-9), according to the authors, who concluded, “We identified a novel synthetic lethality strategy of combining radiation and CD105 targeting to address the DNA repair and metabolic addiction induced by irradiation in p53-functional prostate cancers.”

Madhav A, Andres A, Duong F, Mishra R, Haldar S, Liu Z, Angara B, Gottlieb R, Zumsteg ZS, Bhowmick NA. Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene. 2018 Aug;37(32):4385-4397. doi: 10.1038/s41388-018-0278-0. Epub 2018 May 2. PubMed PMID: 29717261; PubMed Central PMCID: PMC6085281.



Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up